• Company
• BRAF I Braftovi can be prescribed at the Big 5
• by Eo, Yun-Ho Mar 3, 2022 06:01am

• Company
• Entresto settles in as early-stage heart failure treatment
• by Eo, Yun-Ho Mar 3, 2022 06:01am

• Policy
• Ahn Cheol Soo, promised for Vaccine Sovereignty
• by Lee, Jeong-Hwan Mar 3, 2022 06:00am

• Policy
• To establish a pharmaceutical bio-innovation committee
• by Lee, Jeong-Hwan Mar 3, 2022 06:00am

• Company
• Omicron confirmed cases continue to occur in companies
• by Ji Yong Jun Mar 2, 2022 05:55am

• Company
• Keytruda may make ₩300 billion with 1st-line reimb
• by Mar 2, 2022 05:55am

• Company
• Tylenol's sales amounted to ₩83.1 billion last year
• by Chon, Seung-Hyun Mar 2, 2022 05:54am

• Policy
• Negotiations with NHIS on Actemra have been completed
• by Lee, Tak-Sun Mar 2, 2022 05:54am

• Opinion
• [Reporter’s View] Why Big Pharmas 'select and focus'
• by Mar 2, 2022 05:54am

• Company
• Pfizer's 3rd attempt to reimburse ATTR-CM drug ‘Vyndamax'
• by Eo, Yun-Ho Feb 28, 2022 05:55am